Industry outlines its perspective on new third-world vaccine development.
Birmingham
K
K
D003226:Congresses as Topic; D003906:Developing Countries; D015658:HIV Infections / Q000517:prevention & control; D006801:Humans; D008288:Malaria / Q000517:prevention & control; D009316:National Institutes of Health (U.S.); D012106:Research; D013678:Technology, Pharmaceutical; D014376:Tuberculosis / Q000517:prevention & control; D014481:United States; D014612:Vaccines
D014612:Vaccines